<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Duijnstee EA</submitter><funding>Deutsche Forschungsgemeinschaft</funding><funding>Ministerio de Ciencia e Innovaci??n</funding><funding>Eusko Jaurlaritza</funding><funding>Rank Prize</funding><funding>King Abdullah University of Science and Technology</funding><funding>Ikerbasque, Basque Foundation for Science</funding><funding>European Commission</funding><funding>Research Councils UK</funding><funding>University of Warwick</funding><funding>Polymat Foundation</funding><pagination>10275-10284</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10176466</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>145(18)</volume><pubmed_abstract>Formamidinium lead triiodide (FAPbI&lt;sub>3&lt;/sub>) is the leading candidate for single-junction metal-halide perovskite photovoltaics, despite the metastability of this phase. To enhance its ambient-phase stability and produce world-record photovoltaic efficiencies, methylenediammonium dichloride (MDACl&lt;sub>2&lt;/sub>) has been used as an additive in FAPbI&lt;sub>3&lt;/sub>. MDA&lt;sup>2+&lt;/sup> has been reported as incorporated into the perovskite lattice alongside Cl&lt;sup>-&lt;/sup>. However, the precise function and role of MDA&lt;sup>2+&lt;/sup> remain uncertain. Here, we grow FAPbI&lt;sub>3&lt;/sub> single crystals from a solution containing MDACl&lt;sub>2&lt;/sub> (FAPbI&lt;sub>3&lt;/sub>-M). We demonstrate that FAPbI&lt;sub>3&lt;/sub>-M crystals are stable against transformation to the photoinactive δ-phase for more than one year </pubmed_abstract><journal>Journal of the American Chemical Society</journal><pubmed_title>Understanding the Degradation of Methylenediammonium and Its Role in Phase-Stabilizing Formamidinium Lead Triiodide.</pubmed_title><pmcid>PMC10176466</pmcid><funding_grant_id>EP/R029431</funding_grant_id><funding_grant_id>EP/R029946/1</funding_grant_id><funding_grant_id>PID2021-129084OB-I00</funding_grant_id><funding_grant_id>EP/T025077/1</funding_grant_id><funding_grant_id>CH 1672/3-1</funding_grant_id><funding_grant_id>EP/V027131/1</funding_grant_id><funding_grant_id>RED2018-102815-T</funding_grant_id><funding_grant_id>EP/T015063/1</funding_grant_id><funding_grant_id>PIBA_2022_1_0031</funding_grant_id><funding_grant_id>764787</funding_grant_id><funding_grant_id>EC_2022_1_0011</funding_grant_id><funding_grant_id>EP/V010840/1</funding_grant_id><funding_grant_id>EP/L01551X/1</funding_grant_id><funding_grant_id>EP/S004947/1</funding_grant_id><funding_grant_id>EP/T028513/1</funding_grant_id><funding_grant_id>EP/P033229/1</funding_grant_id><funding_grant_id>RTI2018-101782-B-I00</funding_grant_id><funding_grant_id>OSR-2018-CARF/CCF-3079</funding_grant_id><funding_grant_id>861985</funding_grant_id><funding_grant_id>OSR-2019-CRG8-4095</funding_grant_id><pubmed_authors>Nicholas RJ</pubmed_authors><pubmed_authors>Kober-Czerny M</pubmed_authors><pubmed_authors>Ramadan AJ</pubmed_authors><pubmed_authors>Johnston MB</pubmed_authors><pubmed_authors>Nugraha MI</pubmed_authors><pubmed_authors>Snaith HJ</pubmed_authors><pubmed_authors>Matzen A</pubmed_authors><pubmed_authors>Hung EY</pubmed_authors><pubmed_authors>Anthopoulos TD</pubmed_authors><pubmed_authors>Delgado JL</pubmed_authors><pubmed_authors>Sansom HC</pubmed_authors><pubmed_authors>Collavini S</pubmed_authors><pubmed_authors>Sturdza BK</pubmed_authors><pubmed_authors>Wright AD</pubmed_authors><pubmed_authors>Xia C</pubmed_authors><pubmed_authors>Kubicki DJ</pubmed_authors><pubmed_authors>Zhou S</pubmed_authors><pubmed_authors>Gallant BM</pubmed_authors><pubmed_authors>Holzhey P</pubmed_authors><pubmed_authors>Smith J</pubmed_authors><pubmed_authors>Seo S</pubmed_authors><pubmed_authors>Filip MR</pubmed_authors><pubmed_authors>Saha S</pubmed_authors><pubmed_authors>Gedda M</pubmed_authors><pubmed_authors>Lin YH</pubmed_authors><pubmed_authors>Duijnstee EA</pubmed_authors><pubmed_authors>Gutmann MJ</pubmed_authors><pubmed_authors>Lim J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Understanding the Degradation of Methylenediammonium and Its Role in Phase-Stabilizing Formamidinium Lead Triiodide.</name><description>Formamidinium lead triiodide (FAPbI&lt;sub>3&lt;/sub>) is the leading candidate for single-junction metal-halide perovskite photovoltaics, despite the metastability of this phase. To enhance its ambient-phase stability and produce world-record photovoltaic efficiencies, methylenediammonium dichloride (MDACl&lt;sub>2&lt;/sub>) has been used as an additive in FAPbI&lt;sub>3&lt;/sub>. MDA&lt;sup>2+&lt;/sup> has been reported as incorporated into the perovskite lattice alongside Cl&lt;sup>-&lt;/sup>. However, the precise function and role of MDA&lt;sup>2+&lt;/sup> remain uncertain. Here, we grow FAPbI&lt;sub>3&lt;/sub> single crystals from a solution containing MDACl&lt;sub>2&lt;/sub> (FAPbI&lt;sub>3&lt;/sub>-M). We demonstrate that FAPbI&lt;sub>3&lt;/sub>-M crystals are stable against transformation to the photoinactive δ-phase for more than one year </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-05T16:13:58.53Z</modification><creation>2025-04-05T16:13:58.53Z</creation></dates><accession>S-EPMC10176466</accession><cross_references><pubmed>37115733</pubmed><doi>10.1021/jacs.3c01531</doi></cross_references></HashMap>